Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide imaging study in metastatic hormone-sensitive prostate cancer
NL-OMON50224Phase 2Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Leiden University Medical Center. Primary endpoints: Progression-free survival at 6 months, Progression-free survival at 12 months and 3 more. Started Jun 2015; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON50224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50224.